NCT05296044View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

PHASE3UnknownINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

February 28, 2024

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

JT-003

Subjects take the investigational products once a day for 24 weeks.

DRUG

JT-003 Placebo

Subjects take the investigational products once a day for 24 weeks.

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY